Overview Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme Status: Completed Trial end date: 2011-09-01 Target enrollment: Participant gender: Summary The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme Phase: Phase 2 Details Lead Sponsor: Myrexis Inc.